Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

NCT ID: NCT00121875

Last Updated: 2009-09-29

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 1 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2005-06-30
• Study Completion Date: 2008-12-31

Brief Summary

Growth hormone treatment improves body fat distribution but also causes insulin resistance. Scientists have recently linked insulin resistance with special stores of fat in the muscles, which can be measured by magnetic resonance imaging (MRI). The researchers hypothesize that growth hormone will paradoxically reverse the linkage between muscle fat stores and insulin resistance. To assess this association and to investigate the cause(s), the researchers will measure muscle fat stores during growth hormone treatment. Other parameters linked to insulin resistance (glucose tolerance, blood markers, and body composition) will also be assessed. This study may lead to improved strategies for monitoring growth hormone therapy.

Detailed Description

Growth hormone (GH) treatment can cause insulin resistance (IR) despite its overall favorable influence on body fat composition. IR is associated with special stores of fat in the muscle (intramyocellular lipid or IMCL), which can be measured by MRI. The researchers hypothesize that changes in IR during GH treatment will be associated with a predictable, but possibly contradictory, change in muscle fat stores. Girls receiving GH for short stature, due to Turner syndrome or idiopathic short stature (ISS), will be studied both during and without GH treatment to assess the impact of GH treatment on muscle fat stores.

Hypothesis: Girls with Turner syndrome will have increased IMCL, corresponding to their insulin resistance, when compared to girls with ISS. GH treatment may paradoxically reverse this association in girls with Turner syndrome.

Objectives: The objectives are to assess changes in IMCL during GH therapy and to increase the researchers' knowledge of GH action.

Study Design: Prepubertal girls receiving GH therapy for short stature due to Turner syndrome or ISS will be recruited to participate in a crossover study. Subjects will be studied twice: first during GH treatment and at baseline, following washout without GH for 3 months. GH treatment for up to 6 months will be provided for eligible girls not currently receiving GH. Assessments include:

• IMCL (soleus and tibialis anterior) measured non-invasively by proton magnetic resonance spectroscopy (1H-MRS)
• Body composition measured by DEXA and morphometry
• Whole body insulin sensitivity assessed by oral glucose tolerance
• Levels of plasma lipids and hormones

Endpoints: The primary endpoint is to define the effect of GH on IMCL content in girls with Turner syndrome versus girls with ISS. The secondary endpoint is to examine how GH affects IMCL content by identifying correlative changes in plasma hormones and metabolites.

Significance: This study is intended to find improved strategies for monitoring GH therapy. In addition, IMCL is anticipated to be a valuable probe for understanding GH effects on glucose homeostasis.

Conditions

Turner Syndrome; Idiopathic Short Stature

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Turner syndrome

Girls, aged 7-14, with short stature due to Turner syndrome and eligible for growth hormone therapy

somatropin (rDNA)

Intervention Type: DRUG

Form/Strength: 10 mg aqueous suspension; 5 mg/ml

Dosage/Frequency: 0.35 mg/kg/week, daily divided doses

Duration: 6 months with 3-month washout period

Control / idiopathic short stature

Girls, aged 7-14, with idiopathic short stature and eligible for growth hormone therapy

somatropin (rDNA)

Intervention Type: DRUG

Form/Strength: 10 mg aqueous suspension; 5 mg/ml

Dosage/Frequency: 0.35 mg/kg/week, daily divided doses

Duration: 6 months with 3-month washout period

Interventions

somatropin (rDNA)

Form/Strength: 10 mg aqueous suspension; 5 mg/ml

Dosage/Frequency: 0.35 mg/kg/week, daily divided doses

Duration: 6 months with 3-month washout period

Intervention Type: DRUG

Other Intervention Names

recombinant human growth hormone, Nutropin-AQ

Eligibility Criteria

Inclusion Criteria

• Girls, with Turner syndrome or ISS; height standard deviation score (SDS) ≤ -2
• Bone age ≤ 12 years
• Normal birthweight
• Body mass index (BMI) = 10th-90th percentile
• Normal childhood activity; no physical or other limitations
• Normal, balanced diet (20-40% calories from fat)

Exclusion Criteria

• Puberty (beyond Tanner Stage 1)
• Diabetes in subject or first degree relative
• Sex steroid therapy
• Chronic conditions requiring medication (treatment for hypothyroidism is permissible)
• Significant systemic disease (pulmonary, cardiac, renal, or other)
• Non-removable metal

• Minimum Eligible Age: 7 Years
• Maximum Eligible Age: 14 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Massachusetts General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Massachusetts General Hospital

Principal Investigators

Lynne L Levitsky, MD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Locations

Massachusetts General Hospital

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

L3452n

Identifier Type: -

Identifier Source: secondary_id

2004P-002800

Identifier Type: -

Identifier Source: org_study_id